Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Development and Commercialisation of Transbronchial Lung Ablation to Treat Lung Cancer

Project description

A minimally invasive treatment for lung cancer

Lung cancer is the most common cause of cancer-related deaths in Europe, with a dismal five-year survival rate. Although surgical resection of the tumour prolongs survival, only a small proportion of patients are fit to undergo surgery. Scientists of the EU-funded TABLA project have developed a pioneering, minimally invasive device that can destroy the targeted tumour. It employs a catheter system that delivers microwave heating directly to cancer cells. The procedure can be performed in an outpatient setting, improving patient outcomes and reducing healthcare costs. The project will conduct clinical trials to validate the efficacy of the device and undertake the necessary optimisation steps towards device commercialisation.

Objective

Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed
each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds.
The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in
economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery
due to co-morbidities.

Endowave have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive
intervention. The patented technology uses a flexible catheter system, that can be navigated through the patient’s airway to
deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be
delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system.

The global market opportunity for lung cancer exceeds €3.6 billion. Endowave has formed a consortium of leading
companies that seeks to commercial Endowave’s technology and capture this market opportunity. The proposal is seeking
funding to complete the final development of the microwave system, carry out clinical studies achieve regulatory approval.
This will enable Endowave to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative
market penetration forecasts. This project will drive job generation in Endowave and consortium partners as sales volumes
increase.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

IA - Innovation action

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-FTI-2018-2020

See all projects funded under this call

Coordinator

ENDOWAVE LIMITED
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 033 552,62
Address
88 HARCOURT STREET
D02D K18 Dublin
Ireland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 2 905 076,25

Participants (4)

My booklet 0 0